ACE2016 Is an Allogeneic Gamma Delta 2 (γδ2) T Cell Therapy Targeting the Epidermal Growth Factor Receptor (EGFR) in Patients With Solid Tumors. Phase 1 Clinical Study Expected to Begin in H2 2024. ALAMEDA, Calif. and TAIPEI, Feb. 4, 2024 /PRNewswire/ — Acepodia (6976:TT), a clinical…
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
This post was originally published on this site